Novartis Apr 28, 2026 Novartis CEO calls for 'complete rethink' of Europe's drug pricing policies - Fierce Pharma
Novartis Apr 28, 2026 Novartis’ sales dip as generics pressure intensifies, radioequivalents loom - BioSpace
Novartis Apr 28, 2026 Novartis CEO ‘continuing to evaluate’ in vivo CAR-Ts, but no deals in the works - Fierce Biotech
Novartis Apr 27, 2026 Biopharma bites: 'Green shoots' for UK's biotech sector, Ligand buys XOMA and more from AstraZeneca, Novartis - FirstWord Pharma